Credit: K KStock/Adobe stock

With the arrival of Ozempic, Wegovy and other GLP-1 agonists, a weight-loss drug boom is sweeping America, bringing a new wave of hope to the almost 115 million U.S. adults and children classified as obese.

The possibilities for such medications show no sign of stopping there. In March of this year, Novo Nordisk's weight-loss drug, Wegovy, received FDA approval for lowering the risk of developing heart disease. The demand for weight-loss drugs is surging, including from those who don't need them or are not aware of their side effects.

Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.

Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:

  • Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
  • Educational webcasts, white papers, and ebooks from industry thought leaders
  • Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Benefits Sales Strategies
Consumer Driven Health Care
Core and Group Health
Employer-Paid
Wellness